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Human Neurospheroid Arrays for In 
Vitro Studies of Alzheimer’s Disease
Mehdi Jorfi  1, Carla D’Avanzo2, Rudolph E. Tanzi2, Doo Yeon Kim2 & Daniel Irimia  1
Neurospheroids are commonly used for in vitro disease modeling and drug screening. However, the 
heterogeneity in size of the neurospheroids mixtures available through current methods limits their 
utility when employed for basic mechanistic studies of neurodegenerative diseases or screening for 
new interventions. Here, we generate neurospheroids from immortalized neural progenitor cells 
and human induced pluripotent stem cells that are uniform in size, into large-scale arrays. In proof of 
concept experiments, we validate the neurospheroids array as a sensitive and robust tool for screening 
compounds over extended time. We show that when suspended in three-dimensional extracellular 
matrix up to several weeks, the stem cell-derived neurospheroids display extensive neurite outgrowth 
and extend thick bundles of dendrites outward. We also cultivate genetically-engineered stem cell-
derived neurospheroids with familial Alzheimer’s disease mutations for eight weeks in our microarray 
system. Interestingly, we observed robust accumulation of amyloid-β and phosphorylated tau, key 
hallmarks of Alzheimer’s disease. Overall, our in vitro model for engineering neurospheroid arrays is a 
valuable tool for studying complex neurodegenerative diseases and accelerating drug discovery.
Alzheimer’s disease (AD) affects more than 46 million people worldwide, at a global cost of US $818 billion in 
20151–3. Early-onset familial Alzheimer’s disease (FAD) is the hereditary form of AD that appears at an early 
age and is caused by three known genes mutations: amyloid precursor protein (APP), presenilin 1 (PSEN1), 
and presenilin 2 (PSEN2)4,5. AD is characterized by two main pathological hallmarks including deposition of 
amyloid-β (Aβ) plaques, and accumulation of hyperphosphorylated tau (p-tau) protein in axons, dendrites, and 
cell bodies4,6. To date, despite significant progress in understanding the biology underlying the AD pathogenesis, 
no cure exists for this devastating neurodegenerative disease. This is mainly due to the complexity of the human 
brain physiology, the limited access to the human brain tissues, and the limitations of current in vivo and in vitro 
models to fully recapitulate the disease phenotype. Lengthy ‘preclinical’ or ‘prodromal’ phase of AD preceded 
the onset of cognitive impairment by nearly seven years, posing further challenges for clinical trials of new AD 
treatments and therapies7.
Animal studies have contributed immensely to our understanding of the human brain functions8. However, 
current animal models do not always fully recapitulate the human brain physiology. For example, mouse models 
with FAD mutations show toxic Aβ production, but they lack neurofibrillary tangles, another key hallmark of the 
AD in human9,10. It has also been very challenging to fully recreate the AD pathogenesis with induced pluripotent 
stem cell (iPSC) from FAD patients models, likely due to the presence of low level of toxic Aβ in the system11–13. 
These and other limitations of animal disease models has delayed the progress towards finding a therapeutic tar-
get for AD14,15. Better physiologically-relevant disease models are needed to closely recapitulate AD pathology in 
vitro16. For the past five years, an increasing number of reports described in vitro disease models that successfully 
captured various aspects of AD pathology using human neurons derived from iPSC17–30. While the AD-relevant 
phenotypes observed in iPSC-neurons belong to early stages of the disease, these iPSC models have enabled sig-
nificant insights into AD molecular mechanisms.
Two-dimensional (2D) cell culture dishes have been used for over a century to study cell biology. Although 
current 2D cell culture systems offer low cost and simplified platforms for studying AD pathology in vitro, some 
important characteristics of the brain diseases pathology cannot be reconstructed in typical dishes. This is mainly 
due to the complexity of human brain physiology, and its unique features31. Recently, three-dimensional (3D) 
neural cell culture models including brain organoids and neurospheroids have emerged and demonstrated 
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significant potential as in vitro platforms for studying human brain cell biology32–37. We previously showed that 
genetically-engineered human neural stem cells that overexpress genes with multiple FAD mutations, combined 
with 3D Matrigel condition could recapitulate robust AD pathogenesis including the deposition of Aβ plaques 
and tangles in an AD-relevant 3D neural cell culture38,39. The current neurospheroids models utilize cells iso-
lated from primary rat cortex, maintained in culture for relatively short-term frame of one-two weeks and rely 
on self-organization of the cells into neural spheroids40–44. These models were leveraged to recapitulate the dis-
ease phenotype of AD, and glioblastoma, and could provide a reliable alternative to current animal models45–47. 
However, these neurospheroid platforms are difficult to manipulate experimentally and rely on mixtures of sphe-
roids that are heterogeneous in size, which limits the precision of analysis. Neurospheroids models are also sen-
sitive to small variations including cell culture procedure, cell density, passage, and medium composition. This 
leads to neurospheroids that are heterogeneous in biological properties, stage of differentiation, as well as cell 
composition48,49. Altogether, it is very challenging to reproduce and consolidate the data between different studies 
and even different batches48. To show the potential of this exciting 3D brain cell culture model, it is essential to 
engineer a physiologically-relevant platform capable of generating viable, uniform-sized neurospheroids derived 
from human stem cells. Although neurospheroids have been shown to be extremely useful to reproduce neuro-
logical disease phenotypes, no previous study had applied this system to model specific-disease-like phenotypes 
in vitro using homogeneous arrays of human neurospheroids derived from stem cells.
Here, we leverage new tools and stem cell engineering to generate large-scale arrays of physiologically-relevant 
neurospheroids from genetically-engineered human neural stem cells with FAD mutations or human 
iPSC-derived neural progenitor cells. With this approach, we succeeded in generating neurospheroids that extend 
thick dendrites outward and give rise to mature neurons over the course of two to eight weeks in 3D cell culture. 
We show that after eight weeks in culture, the 3D neurospheroids display two main pathological events of AD, 
namely the accumulation of Aβ plaques and phosphorylated tau. We also validate the neurospheroids array as a 
reliable and predictive test bed for high-throughput drug screening.
Results
We generated stem-cell-derived neurospheroids from genetically-engineered ReNcell VM human neural 
stem (ReN) cells38,39 and human iPSC-derived neural progenitor cells (hiPSC) using microfabricated arrays of 
microwells. Unlike the neurospheroids cultured using traditional methods45, which are heterogeneous in size 
(100–800 µm diameter, Fig. 1a), neurospheroids formed by plating ReN and hiPSC cells in the microwells array 
(Supplementary Fig. S1), are uniformly sized, with minimal variability (498.1 ± 5.8 µm diameter) (Fig. 1a, and 
Supplementary Fig. S2). To closely recapitulate the 3D microenvironment of the human brain, we incorporated 
the neurospheroids with a Matrigel matrix. We counteracted the buoyancy of the neurospheroids in the microw-
ells by casting first a thin layer of Matrigel. Following the mechanical removal of the excess above the microw-
ells, a thin layer of Matrigel is formed on top of the array (Supplementary Fig. S1). Neuronal differentiation of 
the human neurospheroids in the ReN cell culture was initiated after 24–48 h by removing the growth factors 
including epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF). For hiPSC culture, neuronal 
differentiation was induced by switching to a differentiation medium. The size of the neurospheroids in Matrigel 
increases during the initial self-aggregation stage of the ReN cells, in the first 48 h, and then remains constant over 
the course of one month culture (Fig. 1a). At the same time, the heterogeneity in size, which is large immediately 
after the start of ReN cell culture, decreases and the neurospheroids become mechanically confined inside the 
microwells (Fig. 1b). Consistent with previous reports that 3D cell cultures provide brain-like environment condi-
tions50,51, we found that neuronal differentiation and neural network-like connections were presented in the neu-
rospheroids array for both two-week-old ReN- and hiPSC-derived neurospheroids (Fig. 1c, and Supplementary 
Movies S1 and S2).
To recapitulate AD hallmarks in vitro, human ReN neural progenitor cells were developed according to our 
previous reports38,39 to express FAD mutations overexpressing human amyloid precursor protein (APP) and 
presenilin 1 (PSEN1). Control (ReN-G2) and FAD-derived (ReN-mGAP) neurospheroids were cultured in 
the array platform with Matrigel and differentiated over the course of 8 weeks (Fig. 1b–d, and Supplementary 
Movies S1 and S2). At 2-week after the start of differentiation in the array, we observed that processes extend 
to adjacent neurospheroids, both in ReN control (ReN-G2) and in ReN FAD (ReN-mGAP) as well as the 
hiPSC-derived neurospheroids (Fig. 1c), suggesting the formation of the neuronal network. After 8-week dif-
ferentiation, the ReN-derived neurospheroids appear connected through robust and thick bundles of neurites 
documented by fluorescence imaging and scanning electron microscopy (Fig. 1c-d).
Two-month-old ReN-derived neurospheroids express different selected neuronal markers (MAP-2, 
microtubule-associated protein 2; NR2B, N-methyl D-aspartate receptor subtype 2B; GAD2, glutamate decar-
boxylase 2, and TH, tyrosine hydroxylase) (Fig. 2). To assess cell death rate/level and apoptotic cells number/level 
in the generated two-month-old ReN neurospheroids, we quantified the expression levels of cleaved caspase-3 
(apoptosis marker) and Hoechst (nuclei marker). Z-stack series of confocal images showed a co-expression of 
positive cleaved caspase-3 and Hoechst in the center of the neurospheroids but the expression level of cleaved 
caspase-3 relatively low (Supplementary Fig. S3). The hiPSC-derived neurospheroids express multiple neuronal 
markers (TuJ1, ß-tubulin III; DCX, doublecortin, and MAP-2) at two weeks differentiation (Fig. 3). Analysis of 
the composite overlay of a series of Z-stack images from the hiPSC-derived neurospheroids to allow visualization 
of the entire neurospheroids displayed positive nuclei (Hoechst) in all focal points at two-week differentiation in 
the 3D culture platform.
To detect and analyze AD markers in FAD-derived human neurospheroids, the neurospheroids were fixed 
with 4% PFA after 8-week differentiation and stained for Aβ and p-tau, the Aß levels in the cell media were 
measured by Aβ ELISA kit and MesoScale Discovery V-PLEX Assay. As previously reported, FAD-derived neu-
rospheroids (ReN-mGAP) showed an increase in Aβ isoforms including Aβ42, Aβ40, Aβ38, and accumulation 
www.nature.com/scientificreports/
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of total and phosphorylated tau (Figs 4 and 5a and Supplementary Figs S4 and S5). When we treated the FAD 
neurospheroids (ReN-mGAP) with a β-secretase inhibitor (LY2886721), all Aβ isoforms (Aβ38, Aβ40, Aβ42) in 
the supernatant cell culture media above the array were significantly decreased compared to control, dimethyl 
sulfoxide (DMSO) treated neurospheroids (Fig. 5b,c and Supplementary Fig. S6).
To further explore the capability of our neurospheroids array platform to accelerate drug screening, we lever-
aged microfabrication and 3D printing techniques to develop a 96-well cell culture plate with 1,536 microwells. 
The 96-well plate is comprised of five main components: (i) a 3D designed and printed 96-well frame, (ii) a 
high-quality commercial glass substrate with high transmittance of over 92% and high optical clarity for fluores-
cence wavelengths, (iii) a microfabricated array with 1,536 microwells (500 µm diameter and 600 µm depth), (iv) 
Figure 1. Generation and 3D differentiation of homogenously-sized human neurospheroids in a 3D array 
platform. (a) The left images show that ReN- and hiPSC-derived neurospheroids generated in 2D cell culture 
dishes are heterogenous in size (phase contrast). The right image shows homogenously-sized neurospheroids 
assembled in the 3D array platform (fluorescence of green fluorescent protein - GFP). The graph shows a 
quantification of ReN-derived neurospheroids diameter over the course of one month in the 3D array platform. 
(b) Images show expression of GFP in ReN-G2 (control) and ReN-mGAP-derived neurospheroids (FAD) 
generated in the 3D platform with Matrigel at 1-week differentiation. (c) Representative confocal images show 
3D differentiation of ReN- and hiPSC-derived neurospheroids and extension of processes between adjacent 
neurospheroids at 2-week differentiation. (d) Scanning electron microscopy (SEM) images show bundles of 
neurites of ReN- and ReN-mGAP-derived neurospheroids at 8-week differentiation in the 3D array platform.
www.nature.com/scientificreports/
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a commercial self-adhesive 96-well silicone superstructure that adheres to the array, and (v) a lid (Fig. 6a). Using 
the 96-well array plate, we generated neurospheroids and treated these with various compounds including γ–
secretase inhibitor (Compound E), β-secretase inhibitor (LY2886721), Imatinib, and Methotrexate. 
Neurospheroids were monitored at five different concentrations for each compound over the course of one week 
(Fig. 6b). DMSO treated neurospheroids were employed as a control. We noted a 20–30% decrease in neurosphe-
roid diameter for the two highest DMSO concentrations. Neurospheroids treated with γ–secretase inhibitor, 
Methotrexate, and Imatinib displayed neurite-like projections (Fig. 6c, and Supplementary Fig. S7). Previously, 
we showed that γ–secretase inhibitor treatments accelerated the neuronal differentiation and neurite-like projec-
tions possibly by blocking the Notch signaling, in human neurospheroid cultures45. As expected, the neurosphe-
roids treated with β–secretase inhibitor did not show any neurite-like projections (Fig. 4c, and Supplementary 
Fig. S7). The neurospheroids treated with γ–secretase inhibitor, Methotrexate, and Imatinib also showed a smaller 
size than the DMSO treated controls (Fig. 4c, and Supplementary Fig. S7).
In addition to the qualitative changes noted by monitoring the shape and homogeneity of the neurospheroids, 
we also quantified the formation of neurites (Fig. 7a, and Supplementary Fig. S8) and the changes in neurosphe-
roid diameter (Fig. 7b, and Supplementary Fig. S8). After five days of exposure to the compounds, we noted a per-
sistent increase in the fraction of neurospheroids with neurite-like projections and a decrease in neurospheroid 
diameter with increasing concentrations of γ–secretase inhibitor (Compound E). These changes were minimal 
in the presence of the β–secretase inhibitor (LY2886721), except for the highest concentrations. The fraction of 
neurospheroids with neurites after exposure to Methotrexate and Imatinib was highest at concentration II and 
Figure 2. Expression of selected neuronal markers in ReN-derived neurospheroids. Two-month-old ReN-
derived neurospheroids express MAP-2, microtubule-associated protein 2, NR2B, N-methyl D-aspartate 
receptor subtype 2B; GAD2, Glutamate decarboxylase 2 (a) and TH, tyrosine hydroxylase (b).
www.nature.com/scientificreports/
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then decreased at higher concentrations. While the diameter of the neurospheroids was reduced, the effect was 
consistent with the toxicity of Methotrexate and Imatinib at concentrations above II.
Discussion
We designed a platform that holds neurospheroids inside microwells-based arrays and employed this tool to rep-
licate key features of the Alzheimer’s disease phenotype in vitro. We leveraged microscale technologies to fabricate 
microwells and generate homogenously-sized neurospheroid arrays derived from immortalized human neural 
progenitor cells (NPCs) as well as hiPSC-derived neural stem cells (NSCs). We added Matrigel to the microw-
ells to hold the newly formed neurospheroids and initiate the differentiation of the neural stem cells into neurons, 
astrocytes, and other types of non-neuronal cells. Adding Matrigel to the microwells is challenging due to the 
intrinsic low adherence characteristic of Matrigel hydrogel to polydimethylsiloxane (PDMS) surface chemistry 
and leads to disorganization of the neurospheroids from their microwell during medium exchanges. We overcame 
these challenges by removing the excess of Matrigel hydrogel after solidifying. The resulting uniform thin layer of 
extracellular matrix covers the neurospheroids in the array as well as the array surface and allows the neurosphe-
roids to differentiate for several weeks.
During differentiation, hiPSC-derived neurospheroids express neuronal markers including ß-tubulin III 
(TuJ1), doublecortin (DCX), and mature microtubule-associated protein 2 (MAP-2). We also show the multiple 
adult neuronal type markers in the 3D cell culture platform including NR2B (excitatory), GAD2 (inhibitory), 
and tyrosine hydroxylase (dopaminergic neurons) in 3D differentiated neurospheroids from ReN cells. This is in 
line with our previous report that we found ReNcell VM cells differentiated in 3D culture conditions expressed 
excitatory, inhibitory and dopaminergic markers, confirming the heterogeneous nature of neurons derived from 
ReNcell VM38. Since mostly hippocampal and cortical neurons are affected in AD, the presence of TH-positive 
dopaminergic neurons may limit the applications of our 3D ReN cell model in studying forebrain-specific 
mechanisms.
One of the interesting aspects of this new model is that the neurospheroids display thick bundles of den-
drites extending outward, different from the current brain organoid models, which show dendrites extending 
inward. This unique design can also accommodate extensive neurite outgrowth and neural networks formation 
between adjacent neurospheroids. While the neurospheroids are confined to microwells, they can be imaged 
repeatedly and indexed based on their location on the plate.
Figure 3. Generation and differentiation of hiPSC-derived neurospheroids in the 3D cell culture platform. 
Representative confocal images show expression of neuronal markers (MAP-2, microtubule-associated protein 
2; TuJ1, ß-tubulin III; and DCX, doublecortin), and nuclei (Hoechst) in the hiPSC-derived neurospheroids at 
2-week differentiation.
www.nature.com/scientificreports/
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For in vitro study of AD pathogenesis and drug treatments, our neurospheroids array tool: (i) provides a plat-
form that helps monitor individual, uniformly-sized neurospheroids during long-term culture, (ii) incorporates 
extracellular matrix proteins that mimic the human brain 3D microenvironment, (iii) takes advantage of 
genetically-engineered human neural stem cells that produce high level of pathogenic Aβ as well as 
physiologically-relevant hiPSC, and (iv) is compatible with high-throughput machines for drug screening. Using 
this platform, we showed that the FAD neurospheroids derived from immortalized ReN cells recapitulate major 
hallmarks of the AD including the accumulation of extracellular Aβ aggregates and intracellular p-tau. Moreover, 
we also observed that the levels of both total and phosphorylated tau were increased in the FAD-derived neuros-
pheroids compared with controls (data not shown). This observation is consistent with recent studies using FAD 
patient-derived neurons, which showed the increase in both total tau and phosphorylated tau at the early stage of 
tauopathy (termed “tau proteostasis”)22. We also demonstrated the capability of the system to block the release of 
pathogenic and non-pathogenic Aβ isoforms by β–secretase inhibitor. Other genetically-engineered cells may 
potentially be used for the study of AD and other neurodegenerative diseases.
Figure 4. Reconstructing Alzheimer’s amyloid and tau pathology in 3D ReN-derived human neurospheroids. 
Representative confocal images show increased Aβ42 deposits and phosphorylated tau in FAD-derived 
neurospheroids after 8-week differentiation. Images show expression of the green fluorescent protein (GFP) 
in the engineered human neurospheroids, microtubule-associated protein 2 (MAP-2, neuronal marker), Aβ42 
(isomer 1–42 Aβ), and p-Tau (phosphorylated tau marker).
www.nature.com/scientificreports/
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Although our FAD neurospheroids model nicely recapitulated the accumulation of amyloid-β and phospho 
tau, our 3D culture models, as well as a majority of the current cellular and animal AD models, require overex-
pression of FAD genes with single or multiple mutations. Since most of AD patients (>95%) do not carry either 
FAD mutations nor FAD gene overexpression (sporadic AD), current cellular AD models with FAD mutations 
may not be suitable for modeling sporadic AD patients. Even iPSC-derived neurons from FAD patients cannot be 
free from this criticism, since they harbor genetic mutations that represent the very small percent of AD patients. 
We believe that developing 3D AD neurospheroid models without carring rare FAD mutations, will be an impor-
tant next step in comprehensively recapitulating AD pathogenic cascade in cellular models.
To validate the use of the neurospheroid arrays as drug screening tools compatible with high-throughput 
screening machines, we developed a new 96-well platform. Using this platform, we tested the quantitative and 
Figure 5. Quantification of changes in amyloid-β and phosphorylated tau in 3D ReN-derived neurospheroids. 
(a) Graphs show a quantitative comparison of immunohistochemical staining measured by mean fluorescence 
intensity of MAP-2, Aβ42, and p-tau levels. (b,c) Graphs show higher Aβ levels in FAD-derived neurospheroids 
(ReN-mGAP) compared to control ReN-G2 as measured by Aβ ELISA kit (b) and MesoScale Discovery 96-well 
Mouse Pro-Inflammatory V-PLEX Assay (c). Treatment with 1 µM β–secretase inhibitor (LY2886721) decreased 
Aβ38, Aβ40 and Aβ42 levels in both ReN-G2 control and ReN-mGAP FAD cell line. *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001; ANOVA followed by a post hoc Tukey’s test; means ± SEM; n = 4 per each 
sample.
www.nature.com/scientificreports/
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qualitative changes in neurospheroids morphology, size and neurite extension in the presence of multiple com-
pounds including the inhibitors of β– and γ–secretases, which have been primary targets for AD drug discovery. 
We found that γ–secretase inhibitor (Compound E) induced abnormal neuronal differentiation in our 3D neuro-
spheroids derived from ReN cells, in the presence of growth factors in the culture medium (EGF, bFGF), which 
they block the neuronal differentiation of the neurospheroids, similar to our previous study45. These results, sug-
gest that the therapeutic inhibition of γ–secretase activity may interfere with adult neural stem cell function in 
patients’ brains. In contrast, β–secretase inhibitor (LY2886721) did not show any evidence of toxicity. One inter-
esting finding of the current drug screening study is the similar trend of cell toxicity showed by all tested com-
pounds at the highest concentration. Part of this effect is likely due to the toxicity of DMSO on neurospheroids, 
consistent with other reports of DMSO toxicity on neuronal cells52. Moreover, we found that Methotrexate53,54 
and Imatinib55,56 at higher concentrations exert a potent effect on neurite-like projections and potential neural 
differentiation in the human neurospheroids. This is in line with previous findings showing that Methotrexate is 
Figure 6. Platform assembly and qualitative evaluation of the ReN-derived neurospheroids in the 3D platform 
under the effect of active compounds. (a) The microfabricated 96-well cell culture plate with 1,536 microwells 
for neurospheroids culture stacks the PDMS array between a glass slide and a plastic superstructure. The 
assembly is mounted inside a 3D printed plate and covered with a lid. (b) The diagram shows the timeline of 
the neurospheroid growth, drug treatment, and analysis protocols. (c) Confocal representative images show a 
qualitative comparison of the neurospheroids size and morphology at day seven after treatment with DMSO 
(control), γ–secretase inhibitor (Compound E), β–secretase inhibitor (LY2886721), Methotrexate, and Imatinib 
at five different concentrations.
www.nature.com/scientificreports/
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neurotoxic to neural progenitor cells and human embryonic stem (ES) cells by inhibiting proliferation while 
inducing neuronal differentiation on ES and progenitor cells in the hippocampus57,58. To the best of our knowl-
edge, the effect of Imatinib on human neural progenitor cells and in particular 3D neuronal brain models such as 
neurospheroids has not yet been reported. More systematic studies are needed to get a deeper understanding of 
the mechanism of these compounds on neural progenitor cells and hiPSC. Overall, this unique platform may 
serve as a reliable, physiologically-relevant human brain cell culture model, and cost-effective high-throughput 
drug screening for not only AD but also for other neurodegenerative diseases.
Methods
Cell culture. ReNcell VM human neural progenitor (Cat. No. SCC008), and human iPSC-derived neural 
progenitor cells (Cat. No. SCC035) were purchased from EMD Millipore, USA. A familial Alzheimer’s disease 
(FAD) cell line that exhibits substantial amyloid pathology was engineered according to the previous reports38,39. 
In brief, immortalized human neural progenitor cell line ReNcell VM (ReN) were transfected with internal 
ribosome entry site (IRES)-mediated polycistronic lentiviral vectors containing FAD-related genes encoding 
human amyloid precursor protein (APP) with both the K670N/M671L (Swedish) and V717I (London) muta-
tions (APPSL), presenilin 1 (PSEN1) with the ΔE9 mutation (PSEN1(ΔE9)) with both GFP and mCherry as 
reporters for viral infection. Fluorescence-activated cell sorting (FACS) was then used to enrich the population 
of cells with the highest expression levels. The ReN and hiPSC cells were cultured in Matrigel-coated T25 cul-
ture flasks (1:100 dilution of Matrigel:DMEM-F12 medium) using ReN cell proliferation medium, or ENStem-
ATM neural expansion medium. ReN cells proliferation medium was prepared by combining 484.5 mL DMEM/
F12 medium (Gibco/Life Technologies) with 0.5 mL heparin (STEMCELL Technologies), 10 mL B27 (Gibco/
Figure 7. Quantification of the effect of γ–secretase inhibitor, β–secretase inhibitor, Methotrexate, and 
Imatinib treatments on homogenously-sized neurospheroids generated in a 3D array platform. (a) The effect 
of γ–secretase inhibitor (Compound E), β–secretase inhibitor (LY2886721), Methotrexate, Imatinib, and DMSO 
(control), on neurospheroids neurites at day seven. (b) The effect of γ–secretase inhibitor (Compound E), β–
secretase inhibitor (LY2886721), Methotrexate, Imatinib, and DMSO (control), on the neurospheroids diameter 
at day 7. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ANOVA followed by a post hoc Dunnett’s test; 
means ± SEM; n = 6 per each sample.
www.nature.com/scientificreports/
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Life Technologies), 5.0 mL of 100X penicillin/streptomycin/amphotericin B (Lonza), 0.5 mL epidermal growth 
factor (EGF, 20 μg/mL, Sigma-Aldrich), and 0.4 mL basic fibroblast growth factor (bFGF, 25 μg/mL, Stemgent). 
Human iPSC expansion medium was prepared by combining 99 mL ENStem-A neural expansion medium (Cat. 
No. SCM004, EMD Millipore) with 1.0 mL EmbryoMax L-Glutamine solution (100X), 200 mM (Cat. No. TMS-
002-C, EMD Millipore) and 1.0 mL EmbyroMax ES Cell-Qualified Penicillin-Streptomycin solution, 100X (Cat. 
No. TMS-AB2-C, EMD Millipore). FGF-2 (Cat. No. GF003, EMD Millipore) was added to the ENStem-A neural 
expansion medium fresh to the final concentration of 40 ng/mL during media exchanges.
Fabrication of the array platform. The masters for preparing the PDMS arrays (500 μm diameter and 
600 μm depth) were designed and microfabricated by patterning SU-8 photoresist (MicroChem Co.) on a silicon 
wafer using standard photolithography techniques59. Devices presenting 5 × 5 microwell arrays were bonded after 
plasma treatment to uncoated 6-well glass bottom plate (MatTek Corporation). The 96-well platform for drug 
screening is composed of five components: (i) a 3D designed and printed 96-well frame, (ii) a high-quality glass 
(Nexterion, Applied Microarrays, Inc.) with high transmittance of over 92% and high optical clarity for fluores-
cence wavelengths, (iii) a microfabricated PDMS microwell array, (iv) a 96-well silicon superstructure (Nexterion, 
Applied Microarrays), and (v) a lid. The microplate frame was designed and printed using a MakerBot Replicator 
2 desktop 3D printer. The master for preparing the PDMS array with 1,536 microwells (500 μm diameter and 
600 μm depth) was designed and microfabricated with SU-8 photoresist (MicroChem Co.) on a silicon wafer. 
The PDMS array was molded by casting the liquid prepolymer composed of a mixture of 10:1 silicon elastomer 
and a curing agent (Sylgard 184). The mixture was cured at 75 °C for 12 h, and then the PDMS mold was peeled 
from the silicon wafer. The molded PDMS block was turned upside down and bonded to the glass substrate using 
oxygen-plasma treatment. Finally, the self-adhesive 96-well silicon superstructure adhered to the 96-well PDMS 
array and all components were assembled into one 96-well plate.
Generation of human 3D neurospheroids from stem cells. Neurospheroids were formed by plating 
30 × 106 cells/mL of the neural progenitor cells derived from ReNcell VM cell (ReN-G2, control cell line; and 
ReN-mGAP, FAD cell line) or hiPSC in expansion medium on top of the array. After 20 min, expansion medium 
was added on the side of the array, and then half of the medium was aspirated to remove floating cells from the 
device. The devices were incubated at 37 °C and 5% CO2 atmosphere. After 24 h, the proliferation medium was 
changed. After 48 h required for complete neurospheroids formation in each well, the proliferation media was 
aspirated, and Matrigel at a dilution of 1:4 in differentiation medium (ReN-derived neurospheroids) and in 1:1 
expansion:differentiation medium (hiPSC-derived neurospheroids) was applied on the top of the array to cover 
the whole surface area. After 24 h required for solidifying Matrigel at 37 °C, the Matrigel on the surface of the 
devices was removed gently using a gel loading tip-tilted into 90 degrees, and the medium was replaced with fresh 
differentiation medium. The cell culture was maintained up to eight weeks, changing the differentiation medium 
every 4 days. ReN cells differentiation medium was prepared by combining 484.5 mL DMEM/F12 medium with 
0.5 mL of heparin, 10 mL of B27 and 5.0 mL of 100X penicillin/streptomycin/amphotericin B. ENStem-A neural 
differentiation medium (Cat. No. SCM017, EMD Millipore) was used for differentiation of human iPSC-neural 
progenitor cells.
Immunofluorescence staining. Neurospheroids were cultured up to eight weeks in differentiation 
medium followed by rinsing in phosphate-buffered saline and fixation in 4% paraformaldehyde (Electron 
Microscopy Sciences) for overnight at room temperature and then washed three times with 1X Tris Buffered 
Saline with Tween 20 (TBS-T). The neurospheroids were immersed for overnight at 4 °C in blocking solu-
tion. Blocking/dilution solution for immunostaining was prepared by adding 2.5 g of BSA (Sigma-Aldrich), 
5.63 g of glycine and 0.25 g of gelatin in 200 mL of TBS-T and heated at 55 °C for ~10 min to allow gelatin 
to dissolve. 10 mL of donkey serum (Sigma-Aldrich) and TBS-T was added to make the final volume of 
250 mL. The blocking/dilution solution was then filtered with a 0.4 μm filter unit (Gibco) and stored at 
4 °C. The blocking step was followed by permeabilization with 0.1% Triton X-100 for 45–60 min at room 
temperature. The cells were washed three times with 1X TBS-T and the neurospheroids were incubated with 
primary antibodies in blocking solution at 4 °C overnight followed by species-specific secondary antibodies 
at 4 °C overnight in the dark (Table S1). The cell nuclei were stained with Hoechst 3342 (1:2000 dilution) 
for 20 min at room temperature. Following staining of the neurospheroids, a series of images were captured 
using the Z-stacking function on an inverted Nikon Eclipse Ti microscope (Nikon Instruments), to allow 
visualization of the entire neurospheroids. The excitation wavelengths of mCherry and anti-chicken Alexa 
fluor 568 antibodies, used for MAP2 staining used for in this study, partially overlap. However, the major 
differences in signal strength allowed us to differentiate the MAP2 signal versus Alexa fluor 568. All images 
were processed using Fiji (ImageJ) software.
Electron microscopy. For Scanning Electron Microscopy (SEM), ReN-derived neurospheroids were fixed 
in 2.5% glutaraldehyde for 30 min, washed three times with PBS, and then post-fixed in aqueous 1% OsO4 for 1 h. 
After washing in PBS three times for 15 min each, they were dehydrated through a graded series of ethanol in PBS 
(30 to 90%) for 15 min each and washed with absolute ethanol three times before they were dried in hexamethyld-
isilazane solution and allowed to air dry under safety hood. Afterwards, the arrays with fixed neurospheroids were 
mounted onto aluminum stubs, sputter-coated with 5 nm of platinum/palladium, and imaged in an Ultra55 Field 
Emission Scanning Electron Microscope (FESEM) at 10 kV with In lens SE detector.
Drug treatments. Neurospheroids were formed by seeding neural progenitor ReN-G2 (12 × 106 cells/mL in 
proliferation medium) on top of the array. After 20 min, proliferation medium was added on the side of the array, 
and then half of the medium was aspirated from the side to remove floating cells from the device. The devices 
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were incubated at 37 °C and 5% CO2 atmosphere. After 48 h, the fully formed neurospheroids in the 96-well plate 
were treated with different drugs in five different concentrations. The ReN-derived neurospheroids were main-
tained for one week, changing the medium with fresh differentiation medium including the drugs after four days. 
After one week, neurospheroids were rinsed with phosphate-buffered saline and fixed with 4% paraformaldehyde 
for overnight at 4 °C and then washed three times with D-PBS. The fixed neurospheroids were imaged using 
inverted Nikon Eclipse Ti microscope (Nikon Instruments).
Quantitative measurement of changes in Amyloid-β. The measurement of Aβ38, 40, and 42 levels 
was performed using two different assays: (i) amyloid-β ELISA—Aβ40 and Aβ42 levels were measured by the 
Human Amyloid-β ELISA Kit (Wako Pure Chemicals, Osaka, Japan). The conditioned media from differenti-
ated ReN neurospheroids were collected and diluted by 1:2 with a dilution buffer provided by the company. The 
Synergy 2 ELISA plate reader (BioTek Instruments, Winooski, VT, USA) was used to quantify Aβ40 and Aβ42 
ELISA signals. (ii) Aβ38, 40 and 42 levels were measured by MesoScale Discovery (MSD, Rockville, MD) 96-well 
Mouse Pro-Inflammatory V-PLEX Assay as outlined in the manufacturer’s protocol. Briefly, 150 μl of Diluent was 
added to the plate coated with an array of Aβ capture antibodies and incubated at room temperature with shak-
ing for one hour, followed by washing with wash buffer (provided in the kit). A volume of 25 μL of the detection 
antibody solution plus 25 μL of prepared samples were added and incubated for 2 h with vigorous shaking at room 
temperature. The plate was washed with wash buffer before adding 150 μL of 2X Read Buffer T, and immediately 
read on a Meso QuickPlex SQ 120.
Statistical analysis. All statistical analyses were performed using GraphPad Prism 7. All results are pre-
sented as box plots, with means, standard error of the mean, 5 and 95% percentiles and outliers. Quantitative 
analysis of cell staining for a particular marker in the neurospheroids were performed using Fiji (ImageJ) soft-
ware. The effects of various drugs on neurospheroids size and neurites at different concentrations were analyzed 
using ANOVA with Dunnett’s multiple comparisons test. Quantitative analysis of Aβ expression was analyzed 
using ANOVA with Tukey’s multiple comparisons test. Differences between means were considered significant at 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files).
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